AIDSmeds Founder Peter Staley interviewed Dr. Alan Tennenberg, Tibotec's VP of Clinical Affairs, regarding the latest clinical data on Prezista, the newly approved protease inhibitor. We also asked him about how the company responded to community demands around pricing.
Click here to listen to the 7 minute interview. (6.4MB mp3 file)
If you don't understand one of the words in this article,
just double-click it. A window will open with a definition
from CancerWEB's On-line Medical Dictionary. If the double-click feature
doesn't work in your browser, you can enter the word below:
